Goldman Sachs’s Seres Therapeutics MCRB Stock Holding History

Goldman Sachs’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,500	Closed	-$172K	–	6432
2022 Q2	$172K	Hold	2,500	–	–	﹤0.01%	5694
2022 Q1	$356K	Buy	+2,500	New	+$385K	﹤0.01%	5556
2020 Q4	–	Sell	-24,450	Closed	-$13.8M	–	5613
2020 Q3	$13.8M	Buy	+24,450	New	+$8.13M	﹤0.01%	2042
2016 Q2	–	Sell	-1,750	Closed	-$930K	–	7154
2016 Q1	$930K	Hold	1,750	–	–	﹤0.01%	4132
2015 Q4	$1.23M	Sell	1,750 -375	-18%	-$246K	﹤0.01%	4095
2015 Q3	$1.26M	Buy	+2,125	New	+$1.73M	﹤0.01%	4244

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Goldman Sachs's MCRB Position: Q2 2026 in Review

Goldman Sachs opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 15,229 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #6311 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in MCRB as recently as Q4 2025.

Goldman Sachs first reported a position in MCRB in Q3 2015 and has held it in 41 quarters since. The position peaked at $18.7M in Q1 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

Goldman Sachs held 15,229 shares of Seres Therapeutics worth $120K as of Q2 2026.
Seres Therapeutics was a new Goldman Sachs position in Q2 2026.
Seres Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6311 holding.
Goldman Sachs first reported a position in Seres Therapeutics in Q3 2015 and has held it in 41 quarters since.
Goldman Sachs's Seres Therapeutics position peaked at $18.7M in Q1 2021.
36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.